Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Medpace Holdings Inc (MEDP) vs ProShares UltraPro S&P500 (UPRO) Price & Performance

Medpace Holdings IncTrade
ProShares UltraPro S&P500Trade

Price performance (Past 24H)

Key statistics

Medpace Holdings Inc vs ProShares UltraPro S&P500 — how do they compare? Medpace Holdings Inc trades at $530.32 (market cap $15.08B), while ProShares UltraPro S&P500 trades at $140.67. The key difference: ProShares UltraPro S&P500 is trading nearer its 52-week high, Medpace Holdings Inc nearer its low. Which is the better fit depends on your goals.

MEDPUPRO
Market Cap
$15.08B
Sector
TechnologyLeveraged / Inverse
52-Week High
$620.59$150.93
52-Week Low
$308.88$89.29
Enterprise Value
$14.55B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Medpace Holdings Inc

MEDP trades at $527.93, down 1.82% today, with a bullish technical outlook supported by moving averages. The company demonstrates strong profitability with 17.19% net margins and 77.25% ROE, though valuation ratios appear elevated with a P/E of 33.83. Recent earnings have consistently beaten expectations, and cash flow is projected to improve significantly in 2026. However, the stock faces headwinds from ongoing class action lawsuits and mixed analyst sentiment with 73.69% hold ratings.

MEDP presents a mixed investment case with strong fundamental performance offset by legal overhangs and premium valuation. The company's consistent earnings beats and projected cash flow improvement support upside potential, but investors should weigh the legal risks and cautious analyst stance against the robust operational metrics.

ProShares UltraPro S&P500

UPRO trades at $138.50, down 0.4% on the day, with a bearish technical signal driven by moving averages. Key support lies at $135, while resistance is at $141. Financial ratios are unavailable, limiting fundamental clarity. Recent news highlights S&P 500 concentration risks and AI-driven market volatility, influencing this leveraged ETF's performance.

The outlook is cautious due to technical weakness and broader market concerns over valuation and tech stock reliance. Risks include market corrections and ETF-specific volatility. Investors should weigh the lack of fundamental data against the leveraged exposure to S&P 500 trends.

Returns comparison

Trailing returns across standard periods

About Medpace Holdings Inc

Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.

Read more on MEDP

About ProShares UltraPro S&P500

UPRO is a leveraged ETF that seeks daily investment results, before fees and expenses, that correspond to three times (3x) the daily performance of the S&P 500 Index. It is a tactical, high-conviction instrument designed for short-term traders to amplify bullish market moves, utilizing a daily reset mechanism that creates significant compounding effects and volatility risks over time.

Read more on UPRO